Abstract: Renal artery stenosis (RAS) is usually caused by atherosclerosis or fibromuscular dysplasia. RAS leads to activation of the renin-angiotensin-aldosterone system and may result in hypertension, ischemic nephropathy, left ventricular hypertrophy and congestive heart failure. Management options include medical therapy and revascularization procedures. Recent studies have shown angiotensin receptor blockers (ARB) and angiotensin converting enzyme inhibitors (ACE-I) to be highly effective in treating the hypertension associated with RAS and in reducing cardiovascular events; however, they do not correct the underlying RAS and loss of renal mass may continue. Renal artery angioplasty was first performed by Gruntzig in 1978. The routine use of stents has increased technical success rates compared with angioplasty, and surgery is now only rarely performed. Although numerous case series claimed benefit in terms of blood pressure control, no adequately powered randomized, controlled, prospective study of renal artery interventions has reported their effect on cardiovascular morbidity or mortality. The CORAL trial, an ongoing study of renal artery stent placement and optimal medical therapy (OMT) funded by the National Institutes of Health, is the first study to attempt to do so. Until the CORAL trial results are in, physicians will continue to be faced with difficult choices when determining the optimal management for RAS patients and deciding which, if any, patients should be offered revascularization.
Introduction
Renal artery interventions (RAI) include percutaneous transluminal renal angioplasty (PTRA), renal artery stenting, and renal artery stent graft placement. The first PTRA was reported by Gruntzig in 1978, 1 and Tegtmeyer reported the first US experience shortly thereafter. 2, 3 While these and subsequent series showed that PTRA was technically feasible and safe, complications and failures (especially in ostial lesions) led investigators to search for other treatment options. Palmaz described the use of renal stents in animals in 1987 followed shortly thereafter by reports of renal artery stenting in humans. 4 Since that time RAI technology has improved considerably, including lower-profile, pre-mounted balloon-expandable stents (3 F to 5 F outer diameter), distal protection devices (DPD) that may help avoid distal embolization, and pressure sensing wires that allow accurate measurement of pre-and post-intervention pressure gradients. At the same time, the widespread availability of duplex ultrasound, magnetic resonance angiography (MRA) and computed tomography angiography (CTA) has led to increased screening for RAS. Between 1996 and 2000 the annual volume of RAI billed to Medicare increased 242%. 5 While new technologies have certainly increased technical success rates and decreased complication rates for RAI, 6, 7 stenting has not shown improved clinical outcomes compared with angioplasty alone. 7 Indeed, there is no adequate scientific evidence that shows clinical benefits of any of these procedures, [8] [9] [10] and it remains difficult to predict the clinical outcome of RAI in any individual. Furthermore, contemporary medications to treat hypertension (HTN), dyslipidemia, and inhibit platelets are known to reduce cardiovascular (CV) events (myocardial infarction (MI), sudden cardiac death, stroke, and congestive heart failure (CHF)). 11 It is difficult to gauge the additional treatment effect, if any, of RAI in addition to optimal medical therapy (OMT).
Renal artery stenosis: epidemiology
Flow-obstructing lesions of the renal arteries may be caused by atherosclerosis, fibromuscular dysplasia (FMD), vasculitis, neurofibromatosis, congenital bands, extrinsic compression, emboli, aortic dissection, and radiation. 12 The majority of patients will have either atherosclerotic RAS or FMD. Atherosclerotic RAS will account for approximately 90% of cases of RAS. 13 The prevalence of atherosclerotic RAS increases with age, particularly in patients with diabetes, hyperlipidemia, other atherosclerotic disease, and HTN. Atherosclerotic RAS is present in 1-5% of the nearly 60 million Americans with HTN, [14] [15] [16] in 30% of patients with coronary artery disease (CAD), 17 7% of those over the age of 65, 18 and in up to 50% of elderly patients with diffuse atherosclerotic disease. 19, 20 Atherosclerotic RAS typically involves the ostium and/or proximal one-third of the renal artery and often the adjacent aorta 21 (Figure 1) . Uncommonly, segmental or diffuse intrarenal stenoses may be present, a pattern that is more common with fibromuscular dysplasia (FMD).
Renal artery stenosis: natural history
The natural history of atherosclerotic RAS has been studied for over 30 years; however, the results have been somewhat inconsistent. Anatomical progression is considered as an increase in the amount or degree of anatomical stenosis. Meaney noted anatomical progression in 36% of 39 patients with atherosclerotic RAS who underwent follow-up arteriography at a mean interval of 27 months. 22 Wollenweber noted progression of RAS in 60% of patients followed over 28 months. 23 Schreiber et al. followed 85 patients for a mean period of 52 months and showed progression of stenosis in 44%, with 14 (16%) developing renal artery occlusion. 24 The risk of progression to occlusion was much higher in renal arteries with >75% stenosis. These studies have been criticized because they were performed when arteriography was the only reliable method of evaluating the renal arteries, which may have introduced patient selection bias since angiograms were usually done for persistent or worsening symptoms. A more contemporary study by Zierler et al. used Doppler ultrasound to study 76 patients with atherosclerotic RAS. The cumulative incidence of progression of atherosclerotic RAS from normal to >60% was 8% at 3 years; however, progression in patients with >60% RAS was 48% at 3 years. All renal arteries that progressed to occlusion (n = 4) initially had >60% stenoses at the initial visit. The cumulative incidence of progression to occlusion for those arteries with a >60% stenosis was 7% at 3 years. 25 There is limited data regarding the impact of RAS on renal size and function; however, it is clear that in some patients there can be a loss of renal mass related to RAS. Guzman used duplex ultrasound to prospectively study 54 patients with >60% atherosclerotic RAS and showed that 26% demonstrated loss of renal size with a mean atrophy of 1.9 cm in length (range 1.2-3.4 cm) at up to 24 months (mean 14.4 months). 26 Schreiber et al. 24 described the anatomical progression of stenosis in 44% of kidneys; however, renal atrophy (loss of renal length of >1.5 cm) affected 70% during a mean follow-up of 52 months. This loss of renal mass is associated with a decline in renal function in some patients, although other factors (such as HTN, diabetes mellitus) also play a role. Connolly et al. studied patients with atherosclerotic RAS and reported the risk of progression to dialysis to be significantly associated with the initial angiographic pattern of disease. The 2-year hemodialysis-free survival was 97% in patients with unilateral RAS, 82% with bilateral RAS, and 45% in unilateral RAS with contralateral occlusion. 27 Atherosclerotic RAS has been reported to account for up to 14-16% of new patients entering dialysis each year in the US. [28] [29] [30] [31] Despite the variability in rates of anatomical progression of atherosclerotic RAS and renal functional deterioration between these studies, several conclusions may be drawn with regard to the natural history of atherosclerotic RAS: (1) atherosclerotic RAS is a progressive disease, especially in cases where stenosis is greater than 60%; (2) the risk of progression to occlusion is rare in normal renal arteries, but up to 16% in stenotic arteries; and (3) renal artery stenosis can lead to loss of renal mass and thereby renal function in some patients.
FMD is a non-atherosclerotic, non-inflammatory vascular disorder that accounts for less than 10% of cases of RAS. 13 The disorder typically affects women between the ages of 15 and 50, though it is seen in all age groups and also in men. Multiple subtypes of FMD have been described, depending upon the portion of the vessel wall that is primarily involved. Ninety percent of cases of FMD will involve the media. Classical FMD, so-called 'medial fibroplasia', involves the arterial media, usually involves the distal two-thirds of the renal artery and its branches, and is characterized angiographically by a 'beaded' appearance where the 'beads' are larger than the normal artery and occasionally associated with aneurysms ( Figure 2 ). Perimedial fibroplasia is the second most common subtype of FMD and may also produce a 'beaded' renal artery; however, the 'beads' are typically smaller than the normal artery. Other more unusual types of FMD (intimal hyperplasia, medial hyperplasia) appear as focal arterial constrictions or longsegment stenoses that may resemble vasculitis (e.g. Takayasu's or giant cell arteritis). The cause of FMD remains unknown, although a genetic predisposition has been noted with a higher incidence of FMD in first-degree relatives of patients with renal FMD and among persons with the angiotensin converting enzyme allele ACE-I. 32 The natural history of FMD appears to be quite different from atherosclerotic RAS. FMD most often presents as new-onset or difficult to control HTN in younger patients. Medial fibroplasia FMD progresses in only 30% of patients. 13, 24, 32 It rarely progresses to thrombosis unless associated with dissection or thrombosis and therefore is generally not associated with ischemic nephropathy. Other subtypes of FMD are more commonly associated with dissection and occasionally thrombosis and thereby can lead to a decline in renal function in some patients. 33, 34 Renal artery stenosis: pathophysiology Obstruction of flow in the renal artery, regardless of etiology, sets up a complex cascade of events throughout the body that remain incompletely understood. The initial response of the kidney to decreased perfusion is activation of the juxtaglomerular apparatus that results in production of renin. Renin promotes the conversion of angiotensinogen to angiotensin I (AT I). AT I is cleaved to angiotensin II (AT II) by angiotensin converting enzyme (ACE) in the lungs (Figure 3) . AT II is known to be a potent vasoconstrictor and to promote the release of aldosterone. More recently, the proinflammatory and toxic CV effects of AT II have been described. 35, 36 With unilateral RAS blood pressure elevation is 'renin dependent' and related to vasoconstriction and increased peripheral resistance. With bilateral stenoses or a single kidney, intravascular volume will increase via the effect of aldosterone and renin production will decrease by a negative feedback mechanism. The net result in such cases is 'volume-dependent' elevation of blood pressure as well as salt and water retention. In addition, activation of the sympathetic and central nervous system are felt to contribute to HTN in the setting of RAS. 37, 38 HTN that is poorly controlled may lead to severe end-organ damage and is one of the most frequent causes of chronic renal failure, left ventricular hypertrophy (LVH), and CHF. When severe increases in blood pressure occur acutely hypertensive encephalopathy or intracerebral hemorrhage may occur. 13 The exact degree of stenosis required to activate the renin angiotensin aldosterone system (RAAS) is not known; however, a decline in renal function upon initiation of ACE-inhibitor (ACE-I) or AT II-receptor blocker (ARB) therapy is an excellent clinical indicator of such. 39 Several studies have suggested that patients with atherosclerotic RAS have a higher risk for CV events (i.e. MI, CHF, sudden cardiac death, stroke) that is out of proportion with the degree of HTN. 23, 40, 41 Conlon performed abdominal aortography on 3987 patients immediately following cardiac catheterization and found >75% atherosclerotic RAS in 4.8% with bilateral RAS in 0.8%. The 4-year unadjusted survivals for patients with and without significant RAS were 57% and 89%, respectively (p < 0.001). 40 In addition, bilateral disease was associated with the 4-year survival of 47% as compared with 59% for patients with unilateral disease (p < 0.001). 40 Adjusted analysis confirmed the relationship between RAS and survival. Whether this is due to concomitant atherosclerotic disease in other vascular beds (carotid, coronary), HTN, or highly associated diseases such as diabetes remains controversial. Oxidative stress has also been proposed to play a significant role in the negative CV pathophysiology of renovascular HTN. 42, 43 Increasingly, AT II has been associated with deleterious CV effects including arterial medial and cardiac myocyte hypertrophy, smooth muscle cell proliferation, plaque rupture, endothelial cell dysfunction, and inhibition of fibrinolysis. 35, 36, 44 Furthermore, LVH has been noted to occur when AT II is present, even when blood pressure is controlled. 45 Aldosterone has also been associated with myocardial fibrosis 46 and renin has vasculotoxic and nephrotoxic effects. 47 These findings support the hypothesis that activation of the RAAS induced by atherosclerotic RAS produces significant CV toxicity beyond simple elevation of blood pressure and that blood pressure control may not be a suitable endpoint by which to judge the success of treatment.
Atherosclerotic renal artery stenosis: clinical evaluation
Despite its prevalence in the population there remains no consensus on the screening of patients for RAS. Atherosclerotic renovascular HTN classically has an onset after the age of 50 years, is 'refractory' to standard medical therapy, and is associated with hypokalemia, worsening renal function upon initiation of ACE-I/ARB therapy, abdominal bruit, or recurrent flash pulmonary edema. 13, 48 Unfortunately, these factors are neither sensitive nor specific for RAS. This leads to a somewhat random evaluation of patients with one or more of these suggestive clinical symptoms. The Joint National Committee (JNC) recommends the medical treatment of patients with HTN and states that "more extensive testing for identifiable causes is not indicated generally unless BP control is not achieved". 49 The American Heart Association (AHA) guidelines 50 suggest that revascularization (and therefore screening) should be considered in certain well-defined clinical scenarios (Table 1 50, 51 ). The AHA has a position on the use of 'drive-by' angiography of the renal arteries in the setting of arterial catheterization for coronary or non-coronary arteriography. In such a setting, the AHA states that renal arteriography is accepted as long as the patient meets the above criteria and consent has been obtained. 52 Various screening tests used to detect RAS include MRA, CTA, Doppler ultrasound US, renal scintigraphy (i.e. captopril scan), peripheral renin levels, renal vein renin sampling, and catheter angiography. Catheter angiography remains the gold-standard for evaluation of RAS, especially in FMD where imaging findings can be subtle. Although used commonly in the past, renal vein renin sampling, peripheral renin levels, and renal scintigraphy 53 have been found to be neither sensitive nor specific and are not routinely recommended for atherosclerotic RAS screening. 13, 54, 55 Duplex US provides images of the renal arteries as well as color flow and waveforms and has been used successfully to evaluate RAS with reports of up to 97% sensitivity and 98% specificity in some dedicated, experienced centers. [56] [57] [58] Others have reported technical failures, related to obesity, kidney position, or bowel gas in up to 20%, which has limited widespread application of US for screening in RAS. 59 A single retrospective study had suggested that the Doppler measurement of the Renal Resistive Index (RRI <0.8) might be highly predictive of the success of revascularization in patients with RAS 60 ; however, this finding has not been validated by others. Prospective studies by Zeller et al. found that a beneficial effect on blood pressure and renal function was achieved in patients undergoing renal artery stent placement, despite elevated RRI. 61, 62 Both MRA and CTA have been documented as having sensitivities and specificities of greater than 90%. [63] [64] [65] Advantages of MRA over CTA include lack of calcification artifact, no need for iodinated contrast, lower contrast reaction rates, and no radiation. Until recently it was thought that gadolinium was safe in cases of renal dysfunction; 66 however, recent data suggest that some caution should be used when administering gadolinium to patients with significantly reduced glomerular filtration rates (GFR). 67 CTA appears to have an advantage in detecting small accessory renal arteries and for claustrophobic patients.
Renal artery stenosis: management options
Given the fact that RAS is a common medical problem that leads to activation of the RAAS in some patients which then leads to the myriad of CV Table 1 AHA indications for screening/revascularization of renal artery stenosis 50, 51 Hypertension that is:
• accelerated -sudden worsening of previously controlled hypertension • refractory -resistant to treatment with at least three medications of different classes including a diuretic • malignant -end-organ damage (left ventricular hypertrophy, congestive heart failure, visual or neurologic disturbance, and/or advanced [grade IV] retinopathy) • associated with a unilateral small kidney • associated with intolerance to medication Renal salvage -unexplained worsening of renal function:
• in the setting of antihypertensive treatment, particularly with an ACE-I or ARB • in the setting of chronic renal disease or not attributable to other cause Cardiac disturbance syndromes:
• recurrent 'flash' pulmonary edema out of proportion to any impairment of left ventricular function • unstable angina in the setting of significant RAS ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; RAS, renal artery stenosis.
effects described previously it is reasonable to seek a treatment that would alleviate the root cause of the problem; that is, it would seem logical to 'fix' the lesion by revascularization. Alternatively, one might argue that the cascade of events set in play by RAS and neuroendocrine changes related to activation of the RAAS are adequately treated by blocking their effects using medications such as ACE-I or ARB. Indeed, it is known that medical therapy can reduce up to 80% of the risks of CV events. 68 In that context, how much more risk reduction can revascularization offer, especially considering procedure risk?
Renal artery stenosis: optimal medical therapy (OMT)
Medical management of patients with HTN and RAS, until recently, had been primarily focused on control of blood pressure alone. The JNC-7 recommends a target blood pressure of <140/90 mmHg or <130/80 mmHg for patients with diabetes or chronic kidney disease (defined as GFR <60 ml/min per 1.73 m 2 or albuminuria >300 mg/d). 49 In the setting of essential HTN, reduction of blood pressure using various medications has been shown to be effective in reducing CV events. 69 The ALLHAT study demonstrated equivalency between classes of antihypertensive medications for coronary heart disease events in patients with essential HTN; 70 however, ACE-I and ARB medications have shown the most promise in preserving renal function. 71, 72 Several trials have shown that RAAS inhibiting drugs can slow the progression to end-stage renal disease 71, [73] [74] [75] in patients with essential HTN. Combination treatment with ARB and ACE-I was more effective in slowing the progression of non-diabetic renal disease than either drug alone. 76 Recent studies also suggest that RAAS inhibition decreases CV events beyond blood pressure-lowering effects 72, 77 and that ARBs especially may even reverse LVH. 78 JNC-7 provides no specific treatment for patients with atherosclerotic RAS and HTN but does recommend ACE-I or ARB use in patients with chronic renal disease. 49 While ARB or ACE-I may be optimal for patients with HTN and RAS, some patients with RAS will not tolerate ACE-I or ARB and/or will experience a decline in renal function related to ischemia induced by these agents that is usually, but not always, reversible. [79] [80] [81] Given the high risk of CV events in patients with atherosclerotic RAS, optimized medical care today would include lipid-lowering medications (HMGCoA reductase inhibitors or 'statins') and antiplatelet therapy (aspirin or other agent), tight glucose control for diabetics (target HgbA1C <7 mg/dl), and smoking cessation. Studies have shown that statins can reduce CV events in most at-risk groups, including those with advanced renal disease. 82 Antiplatelet medications have also been shown to reduce CV events in high-risk patients. 83 Tight glucose control using oral agents/insulin for patients with diabetes has been shown in some studies to reduce MI, death, and amputation rates. 84, 85 While medical treatment is clearly beneficial, the costs of lifelong medication to treat HTN must be considered. Poorly tolerated side effects of medications (i.e. fatigue, cough, sexual dysfunction) affect quality of life and reduce compliance. [86] [87] [88] [89] Adherence to published guidelines for the treatment of HTN is poor, mitigating many of the benefits of these medications. 90 Studies suggest that only 50% of patients adhere to their antihypertensive medication regimen and that only 33% are well controlled. 91 Such data suggest that any treatment that would reduce dependence on medications, including renal artery revascularization, potentially could have a beneficial effect on outcomes.
Renal artery revascularization
The unilateral aortorenal bypass procedure was once the only method for renal artery revascularization. Subsequently, other methods were developed, including extra-anatomic bypass procedures (i.e. splenorenal and hepatorenal bypass) and renal endarterectomy. Improvements in techniques have increased technical success rates and surgical options 92 ; however, complications remain considerable. Complications associated with surgery include significant bleeding requiring surgery (1-4%), early graft thrombosis (0-4%), cholesterol embolization (1-4%), MI (2-9%), stroke (0-4%), and death (2.5-8%). [92] [93] [94] [95] [96] [97] [98] [99] [100] Early graft failure, CAD, uncontrolled HTN, and concomitant abdominal aorticaneurysm repair have all been associated with increased perioperative mortality. Early graft failure (2-10%) is highly associated with perioperative death and is most often related to technical problems. 92, 101 Graft patency has generally been favorable, with 5-year combined patency rates of 82-94%. [100] [101] [102] Late failures are generally related to intimal hyperplasia or progressive atherosclerosis. Nephrectomy (or percutaneous embolization) remains an option for patients with unilateral stenoses and uncontrollable HTN that cannot be successfully revascularized.
RAI can include renal artery angioplasty, stent placement, or stent-graft placement. These techniques are all predicated on the basic technique of transluminal angioplasty first described by Dotter and Judkins in 1964. 103 It was known as early as worldwide experience in the early 1980s confirmed the technique's usefulness. 2, 3 Pooled data from multiple studies confirm that complications related to PTRA are less than those associated with open surgical procedures. These include access site hematoma (<3%), clinically apparent distal embolization/occlusion (2.2%), cholesterol embolization (1.1%), and injury requiring renal surgery/nephrectomy (2.5%). 96, [104] [105] [106] PTRA has proven most useful in cases on non-ostial RAS and FMD. PTRA of 'typical' FMD ( Figure 2 ) for patients with HTN is associated with technical success rates of 82-100% with recurrence in approximately 10%. 32, 107, 108 Complicated FMD that includes aneurysms, complex dissections, or failed PTA may require adjunctive stent placement, stent-graft placement, coil embolization, or surgery.
The technical results of PTRA in the treatment of atherosclerotic RAS have not been as good. This may be due to elastic recoil, large plaque burden, or dissection. Most notably, PTRA is especially limited at the renal ostium (variably defined as 5 mm or less from the aorta) where 75% or more of lesions occur in the setting of atherosclerotic RAS (Figure 1) . In this setting, PTRA may fail in up to 75% of cases. [109] [110] [111] These limitations have been overcome, to an extent, by the availability of renal artery stents. First described in 1987, 112 early studies confirmed the benefits of stents in overcoming many of the limitations of failed PTRA. 4, 113, 114 Stents resulted in higher technical success rates and offered the possibility of treating complications such as dissection. A randomized trial in 1999 comparing PTRA to renal artery stenting showed higher technical success rates (57% vs 88%) and 6-month primary patency rates (29% vs 75%) with similar complication rates. 7 Interestingly, there was no difference in clinical outcomes in this series. 7 A meta-analysis of stent series (687 patients, 14 studies) in 2000 reported a 98% technical success rate and complications in 6%. 6 Recent single-center studies (300 and 215 patients) have reported 100% technical success rates with complications in less than 3%. 61, 115 Although some may argue that primary stenting leads to 'overuse' of stents in some patients in which PTRA would have sufficed, 116 most studies support the widespread application of primary renal artery stenting for atherosclerotic RAS.
Two important limitations of renal artery stent placement that have not been completely overcome with the advent of stents include restenosis and distal embolization. Both are important considerations as they have profound implications on the benefits and overall cost of the procedure. Restenosis (generally defined as >50%) rates have ranged from 11% to 39% at 1 year. 4, 117, 118 A meta-analysis performed in 2000 reported a statistically significant reduction in restenosis for stenting compared with PTRA (17% vs 26%). 6 Because most studies are limited by the short duration of follow-up (mean 16 months; range 6-29 months) and inconsistent use of imaging (angiography or duplex US) to assess the patency, it remains difficult to know the true rate of restenosis. Restenosis has been correlated with post-deployment vessel diameter, especially when 4.5 mm or less. 115, 119 Although there has been interest in drug-eluting stents in the renal arteries, there is currently no data supporting their use in limiting restenosis, and one study showed marginal differences in restenosis rates between drug-eluting and bare metal stents. 120 Distal embolization may occur at the time of aortic catheterization, PTRA or renal artery stent placement. Although clinically apparent distal embolization is uncommon during RAI (0-3%), embolization of atheroemboli, acute thromboemboli, or cholesterol emboli may lead to leg or foot pain ('blue toe syndrome'), bowel ischemia, or skin injury ('livedo reticularis'), or a decline in renal function. 121, 122 Furthermore, it has been suggested that atheroemboli during revascularization are associated with decreased survival. 123 Ex-vivo data confirms that large numbers of embolic particulate matter are released during RAI. 124 Distal protection devices (DPD), including filters, baskets, nets, and balloons currently used in carotid artery stenting procedures may offer a means of preventing such emboli.
There is limited but promising clinical data on DPD for renovascular interventions at the present time. Early work was done by Henry in 2001 who reported experience with the PercuSurge (Medtronic/AVE; Minneapolis, MN, USA) device, retrieving debris from 100% (28 of 28) patients. 125 Hagspiel reported the attempted use of the FilterwireEX (Boston Scientific, Natick, MA, USA) in five renal arteries but achieved success only in three. 126 Interestingly, debris was retrieved from all three. Edwards et al. were able to successfully deploy the Guardwire (Medtronic AVE, Minneapolis, MN, USA) in 88% of cases and retrieved visible debris in 44%. 127 These experiences underscore the difficulty of using DPD in renal arteries due to proximal bifurcations and sometimes tortuosity. As most of the currently available devices have been designed for the carotid arteries they are not ideally suited to renal anatomy. Holden et al., using the Angioguard (Figure 4 ) device (Cordis Endovascular, Miami, FL, USA), reported a debris retrieval rate of 65%. 128 While such data are promising, there remains much to be learned about DPD renal arteries. Future device innovations should assist in achieving technical success as newer devices will accommodate renal anatomy better than current devices. The amount of benefit from such devices, however, remains debated due to the lack of published controlled studies on their use.
Comparing treatments for RAS
Given the profound implications of atherosclerotic RAS on the physiology and CV risk there is a need for scientific data on treatment-related outcomes (blood pressure control, strokes, MI, progression to dialysis, mortality) to assess the 'ideal' treatment for atherosclerotic RAS. Because all published studies have been limited in some way, no convincing conclusions regarding the 'appropriateness' of RAI can be made for any population, 129, 130 although one small series of 28 patients with bilateral RAS showed statistically significant blood pressure outcomes after angioplasty. 10 Realizing the limitations, it is nonetheless informative to review the literature that is available.
Renal artery revascularization and hypertension
Studies on renal artery revascularization for blood pressure control have been plagued by small numbers of patients, lack of randomization, inconsistent follow-up, and inconsistent use of definitions of success in terms of blood pressure control. 129 Using such definitions, PTRA for RAS associated with FMD has achieved cure in 40% and improved the control of HTN in 51% of patients, with cumulative clinical success in 87% over 10 years. 107, 131, 132 Surgery is generally performed only for complex FMD or failures of percutaneous intervention. [133] [134] [135] Case series of patients with atherosclerotic RAS report cure of HTN in less than 10% (range 0-19%) and improvement in 53% (range 42-63%). 6, 106, 110, 113, 115, 116, 118, [136] [137] [138] [139] [140] Results of surgical series are similar, albeit with higher complication rates and higher costs. 92, 141, 142 Multiple parameters (clinical, biochemical, radiological, anatomical) have been evaluated for their utility in predicting which patients are most likely to benefit from RAI in terms of blood pressure control. Clinical parameters that have been associated in single-center series with higher rates of improvement in blood pressure control include bilateral disease, 10, 143 higher mean arterial pressure, 115, 143 and the number of pre-procedure medications. 61 Unfortunately, none of these parameters has been consistent across series. Biochemical markers such as renal vein renin levels have been shown to be insensitive in predicting response. 54 More recently, brain natriuretic protein (BNP) has been suggested as being elevated in patients who are likely to respond to RAI for atherosclerotic RAS. In one small series, 77% of patients with elevated BNP had an improvement in BP compared with 0% of those without elevated BNP. 144 Anatomical parameters such as the degree of stenosis have also been touted as predictors of benefit after RAI; however, there is great variability in defining what is a 'significant' stenosis. Most authors would agree that a stenosis would have to be at least 70% or have a 10 mmHg mean/ 20 mmHg systolic gradient to be clinically significant, 50 though there is some variability in measuring both stenoses and pressure gradients and no consistent response based upon degree of stenosis has ever been demonstrated. More recently, the renal fractional flow reserve (RFFR) has been described as a potential way to better determine the physiological importance of lesions. RFFR translesional pressure gradients are measured before and after administration of papaverine 145 and a ratio is obtained. In one series, 86% of patients with an abnormal RFFR had improvement in blood pressure compared with 30% in the normal RFFR group (p = 0.04). Translesional pressure gradients (resting, peak, or hyperemic) alone failed to differentiate blood pressure responders from non-responders. While this data is intriguing, it will require further validation in larger series that include more patients.
There have been three prospective randomized trials that failed to show a statistically significant benefit of RAI compared with medical therapy. [8] [9] [10] Each of the studies has serious limitations. The EMMA 8 and Scottish and Newcastle 10 studies compared PTRA without stents to medical therapy and the DRASTIC (Dutch Renal Artery Stenosis Intervention Cooperative) 9 study used stents only for angioplasty failures. In the DRAS-TIC study, 44% of patients assigned to medical therapy crossed over to RAI, thereby on an intentionto-treat basis assigning any hypertensive benefit in these patients to medication alone. Despite this, the investigators found that patients undergoing RAI were more likely to have 12-month blood pressure improvements (68% vs 38%) or cure (7% vs 0%) and were less likely to have blood pressure deterioration (9% vs 33%). The EMMA study found that both systolic and diastolic blood pressures were reduced by 6 mm more after PTRA than with medical therapy alone (only diastolic change was significant) and that the PTRA group required approximately half as many medications. 8 Interestingly, the Newcastle study noted a significant reduction in blood pressure of 26/10 mmHg only in the subgroup with bilateral stenoses, but this included only a total of 28 patients. 10 There is no prospective randomized controlled clinical trial that proves the superiority of RAI compared with OMT alone for the treatment of atherosclerotic RAS-related hypertension.
Renal artery revascularization and renal function
Studies of renal functional outcomes are generally flawed in that adequate outcome measures have only rarely been used to measure renal function. Most studies that examine the effects on renal function have focused on serum creatinine (SCr) rather than the GFR as recommended by current guidelines 50 or have not consistently reported renal functional outcomes, and all published series have no control group. The STAR 146 and ASTRAL 147 studies in Europe will employ control groups when comparing RAI and medical therapy with medical therapy alone; however, these studies have not yet been published. Nevertheless, many cohort studies have suggested that renal artery revascularization procedures will lead to a sustainable reduction in the slope of the inverse of serum creatinine over time, suggesting a delay in the rate of progression of renal failure. Hunt et al. in 1974 reported on surgical revascularization and described an improvement in SCr compared with medically treated patients. 148 An analysis of 11 observational studies (447 patients) of RAI showed that SCr levels were reduced in 39% (range 17-60%), remained the same in 48%, and were worsened in 11%. 149 Conversely, in the largest series of renal artery revascularization surgery that reported renal function outcomes, Textor reported improvement in 27%, no change in 54%, and worsening in 19%. 150 More recently, Holden and Hill reported 63 patients who received renal artery stent placement with distal embolic protection and achieved an improvement or stabilization of renal function in 94% at a mean follow-up of 16 months (range 6-27). 151 Worsening of renal function occurred in one patient. Watson et al. have demonstrated that the rate of decline of renal function was decreased in all patients who underwent renal artery stenting. 152 In contrast, the three prospective randomized trials comparing RAI to medical therapy have failed to conclusively demonstrate differences in renal functional outcomes for renal artery stenting compared with medical therapy alone. [8] [9] [10] While this in part may be related to the high number of patients treated primarily for HTN rather than azotemia in these studies, the fact remains that there exists no conclusive evidence that renal artery stenting is superior to medical therapy for the preservation of renal function. Promising ongoing investigations include the STAR and ASTRAL trials. Both are prospective randomized studies comparing the effects of medical therapy with RAI to medical therapy alone on the primary endpoint of renal function. 146, 147 Consistent and reliable predictors of a favorable response to RAI in terms of renal function remain elusive. Various clinical, biochemical and radiological parameters have been evaluated for their ability to predict blood pressure response in much the same way that they have been examined for their ability to predict blood pressure response. The data in this area are inconsistent. For example, while Rundback concluded that lower baseline SCr was associated with improvement following stenting, 153 Lederman found that higher SCr was associated with improvement. 115 As previously described, there have also been conflicting reports on the utility of the RRI to predict renal functional improvement after renal artery stenting. 60, 62 Recent work suggests that a more rapid decline in renal function correlates with improved renal function following intervention, 154, 155 although this data will need to be verified in other studies. Similar to blood pressure, there remains no single consistently reliable predictor by which to select patients.
Renal artery revascularization and cardiovascular morbidity and mortality CV events and outcomes following renal artery revascularization procedures have not been evaluated in many series. As with BP and renal functional outcomes, some non-randomized cohort studies have suggested a CV disease risk benefit in patients treated with renal artery revascularization. Hunt et al. reported lower rates of mortality, MI, and stroke in patients undergoing treatment with renal artery bypass surgery and medication compared with those receiving medication alone, with 80% survival in the revascularized group compared with 64% in the medication group over an average follow-up of 7 years. 148 Although not randomized, they claim that those who underwent revascularization were worse clinically and more likely to experience CV events and death a priori, although that is impossible to verify. 148 Interestingly, Pizzollo et al. more recently reported CV outcomes in two cohorts treated with renal artery stent placement and medications, respectively, and showed a similar treatment effect favoring the stent group. 156 Dorros reported a series of 145 patients treated with renal artery stents and showed a cumulative survival of 74% at 3 years. Survival was 92% in patients with normal baseline renal function, 74% in those with mildly impaired renal function, and 52% in patients with elevated baseline creatinine levels (>2.0 mg/dl). The combination of impaired renal function and bilateral disease adversely affected survival. 137 Only two randomized studies have compared CV outcomes in patients undergoing RAI versus medical therapy, and both were underpowered and had little likelihood of showing a difference. The study of 55 patients by Webster et al. found no differences in event rates for CHF, stroke, or MI during a follow-up of 54 months between medical and RAI patients. 10 Balk et al. randomized 52 patients with >75% atherosclerotic RAS to medical versus surgical therapy and found no difference in stop points that included CV events. The paucity of randomized data and lack of OMT in these series makes it difficult to draw conclusions from these studies with regard to differences in important clinical outcomes. 129 An interesting indication for revascularization is that of recurrent CHF and unprovoked pulmonary edema (i.e. the so-called 'flash pulmonary edema'). LVH and decreased contractility, both significant risk factors in the development of CHF, are significantly more common in patients with renovascular HTN compared with essential HTN. 157 Studies have shown that LVH can be partially reversed by both renal artery stenting 158 and medications. 44, 78 These patients often have significant bilateral stenosis 159 or stenosis in a single kidney. Following revascularization, 77-94% of such patients had no hospitalization for flash pulmonary edema. 160, 161 For example, in one series, the number of hospitalizations due to CHF in the year preceding renal artery stenting was 2.4 ± 1.4 and post-stenting was 0.3 ± 0.7 (p < 0.001). 160 It is unclear whether this is due to the effect of revascularization or the beneficial effects of the increasing use of ACE-I from 15% pre-intervention to 50% post-intervention.
Comparing revascularization versus medical therapy: rationale for the CORAL trial
The CORAL study was designed to test the hypothesis that optimal medical therapy (OMT) with stenting of hemodynamically significant atherosclerotic RAS in patients with systolic hypertension reduces the incidence of adverse CV and renal events (www. coralclinicaltrial.org). The CORAL study is truly a pivotal study, whose results will be used to inform clinical decision making for the large number of individuals with atherosclerotic RAS for many years to come. In the CORAL study, OMT is driven by accepted clinical practice guidelines and the latest information available. It includes ARBs as first-line antihypertensive therapy with the aggressive sequential addition of multiple classes of agents until blood pressure control is achieved. OMT also includes aggressive control of diabetes and lipid profiles with monitoring of HgbA1C (goal <7 mg/dl), liberal use of statins to reduce LDL < 100 mg/dl, antiplatelet medications, and smoking cessation programs (Table 2) . Patients eligible for CORAL must have hemodynamically significant stenoses at least 60% by diameter and hypertension on at least two antihypertensive agents of different classes. The primary endpoint is event-free survival from CV and renal adverse events (defined as a composite of CV or renal death, stroke, MI, hospitalization for CHF, progressive renal insufficiency, or the need for permanent renal replacement therapy). Secondary analyses include all-cause mortality, longitudinal renal function, systolic blood pressure, renal artery patency, RRI and preservation of renal function, correlation between stenosis severity and kidney function, quality of life, and cost effectiveness.
The study is a prospective, multicenter (approximately 100 sites), unblinded, two-arm study that will randomize 1080 patients. Patients with clinical evidence for atherosclerotic RAS will be screened for participation, and those with documented systolic hypertension of ≥140 mmHg on ≥ two antihypertensive medications, or with stage II chronic kidney disease will be considered. Major exclusion criteria include patients with a kidney less than 7 cm, SCr >3.0 mg/dl, FMD or non-atherosclerotic RAS, major stroke within 6 months, major trauma or surgery within 30 days, hospitalization for heart failure within 30 days, and MI or unstable angina within 30 days. Randomization and stent therapy will occur at the time of the invasive assessment. Patients randomized to the stent therapy arm are treated by implantation of a Genesis stent (Cordis, Warren, NJ, USA). The study will have over 80% power to detect a threshold of effect size of 25% with a sample of 1080 randomized patients. As mentioned, the CORAL study is the pivotal study of atherosclerotic renal artery stenting, on a par with large randomized clinical trials of carotid artery or coronary bypass surgery (NASCET and CASS, respectively), and if successfully completed will inform treatment decisions indefinitely into the future.
Conclusions
Atherosclerotic RAS is an increasingly recognized disease that results in activation of the RAAS and renovascular hypertension in some patients. The neuroendocine effects of RAAS activation lead to significant CV and renal morbidity in such patients. Although advances in medical therapy continue to improve outcomes for patients with essential HTN and CV disease, their overall benefit in patients with atherosclerotic RAS remains unknown. Advances have also been made in revascularization procedures such that renal artery stenting can be performed successfully in almost 100% of patients with significantly lower complication rates compared with surgery. To date, published randomized clinical trials have failed to prove conclusively that renal artery intervention significantly improves blood pressure, preserves renal function, or reduces episodes of CHF in patients with atherosclerotic RAS despite the number of cohort studies that suggest benefit. Whether renal artery revascularization reduces the incidence of CV events such as death, heart attack, or stroke is also unknown. Given the prevalence of atherosclerotic RAS and the high associated morbidity and mortality, the importance of successful completion of the CORAL study can not be over-emphasized.
